Waltham, Massachusetts, United States · On-site
$375k–$425k/yr
Senior Vice President, Immunology Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes …
Skills: Immunology, Immuno-oncology, Drug discovery, Translational science, Target identification
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
The Senior Vice President of Immunology will lead the research strategy and execution for the company's immuno-oncology pipeline, overseeing target validation and translational science from discovery through clinical development. This role involves building and mentoring a high-performing scientific team while managing external collaborations and contributing to portfolio-level decision-making.
Candidates must hold a PhD or MD/PhD in immunology with at least 15 years of progressive scientific leadership experience in the biotechnology or pharmaceutical industry. A proven track record of advancing drug discovery programs into clinical development and deep expertise in biologics and immuno-oncology are required.
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
The Senior Vice President, Immunology will lead the strategy and execution of immunology and immuno-oncology research at Xilio, working collaboratively with colleagues across the company and with outside partners to advance the company's pipeline of tumor-activated I-O molecules and to extend the platform's reach into adjacent immunology applications. The role spans target identification and validation, candidate profiling in complex immunology assays and translational immunology — from early discovery through IND-enabling activities and into clinical development support. This is a highly visible role with important leadership responsibilities extending beyond management of the immunology function, including oversight of external collaboration programs, business development and KOL engagement.
The high performing professional who fills this position must bring deep scientific expertise in immunology, a track record of leading drug discovery programs to the clinic, and the judgment to set scientific priorities in a fast-paced, resource-disciplined environment. The role requires someone who can immediately contribute to ongoing programs while also shaping where the immunology function and the platform go next. The Senior Vice President must engender credibility and confidence within and outside the company and do so as an effective communicator, collaborator, and developer of scientific talent.
The position will report to Xilio's Chief Scientific Officer and join a talented and experienced research and development organization. He/She/They will work closely with colleagues across research, translational science, clinical development, CMC, and regulatory, as well as with an extended network of external academic collaborators, key opinion leaders, consultants, and CROs. Additionally, the Senior Vice President, Immunology will be responsible for hiring and developing additional immunology talent as the function grows.
I-O/Immunology Research Strategy
Discovery, Preclinical, and Translational Science
Portfolio Contribution and Program Planning
External Innovation and Partnerships
Team Leadership and People Development
Function Leadership and Budget
Immunology and Immuno-oncology Scientific Depth
Biologics Drug Discovery
Leadership
Executive Presence
Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and developing our existing and additional employees. We are committed to equal opportunity and inclusion across all aspects of our organization, including in our recruitment, advancement and development practices. We conduct annual performance and development reviews for each of our employees to discuss the individual’s strengths and development opportunities, career development goals and performance goals. We also regularly survey employees to assess employee engagement and satisfaction. In addition, each regular full-time employee is provided an allowance and time to attend appropriate job-related trainings and other professional development courses, seminars, meetings, and similar sessions. If you are an individual with a disability who requires an accommodation with the hiring process, please reach out to [email protected].
The pay range for this position is $375,000.00-$425,000.00. This pay range represents a good faith estimate of the annual salary for this role. Final compensation may be higher or lower depending on the candidate's qualifications.
Focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients
Xilio is a Waltham, Massachusetts-based clinical-stage biopharmaceutical company focused on defeating cancer. The company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.
Offices: 828 Winter St, Waltham, Massachusetts 02451, US
Focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients
Xilio is a Waltham, Massachusetts-based clinical-stage biopharmaceutical company focused on defeating cancer. The company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.
Offices: 828 Winter St, Waltham, Massachusetts 02451, US
